Page 1 of 1

MHRA issues MS treatment risk update

Posted: Fri Mar 04, 2011 6:22 am
by MSUK
Image


Risk of progressive multifocal leukoencephalopathy (PML) is increased in patients receiving natalizumab (Tysabri) who have had previous immunosuppressant treatment.

The UK medicines regulator MHRA has issued a new warning over the MS treatment natalizumab (Tysabri).

There is already a risk of progressive multifocal leukoencephalopathy (PML) with the treatment, which was known when it was given a licence. PML is a potentially deadly - but rare - progressive, and demyelinating brain disease.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1905

Re: MHRA issues MS treatment risk update

Posted: Fri Mar 04, 2011 9:01 am
by HarryZ
squiffy2 wrote:Image


Risk of progressive multifocal leukoencephalopathy (PML) is increased in patients receiving natalizumab (Tysabri) who have had previous immunosuppressant treatment.
I"m surprised that they are just now starting to advise Tysabri patients of this increased risk. It is a well known fact that previous users of immunosuppressant drugs are in a higher risk category for PML. Makes you wonder.

Harry